EN DE
Watch Illumina Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Illumina Inc (ILMN) fair value: what the stock is really worth

As of Nov 4, 2026: fair value (intrinsic value) of Illumina Inc stock $262, price $227, upside +15.7%, quality 83 out of 100. Rating: undervalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

II Illumina Inc logo Some data Nov 4, 2026

Illumina Inc

ILMN · US
Undervalued, in an uptrend

The stock costs 14% less than our calculation considers fair.

Fair value $262.03 · Undervalued (14%)
Quality 83/100
Solidly profitable · 19.7% net margin (TTM) · excl. goodwill write-downs +20.2%
Generates free cash flow
Positive coverage
Profit last quarter +46% vs. a year ago.
Mixed Growth (revenue YoY −0.8 %/yr in USD)
Moderate debt
Mixed vs. peers (6/14)
Wide moat 77/100 · thin data
Insiders sold $592.2M (6M)
Some data
Quality growth

Risks from the AI analysis

🚩China ban enables local sequencer substitution🚩AI boosts long-read rivals' competitiveness
Watch Illumina Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$510.54 $70.30 Fair Value $262.03 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.

How to read this chart

60‑month range $70.30 – $510.54 · fair‑value band $145.54 – $355.23 · the $226.54 price screens below the $262.03 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.

Follow Illumina in your weekly email

Every Wednesday you see whether Illumina is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.

Show moreShow less

The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services.

The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies.

The company markets and distributes its products directly to customers, as well as through life-science distributors.

The company has a collaboration with Labcorp Holdings Inc. for the development of oncology treatments through applications of sequencing solutions across the healthcare ecosystem; and strategic collaboration with Integrated DNA Technologies to enable a DRAGEN, secondary analysis pipeline for IDT xGena, FFPE and cfDNA next generation sequencing (NGS) library preparation with custom panels, delivering an integrated, end-to-end solution for somatic oncology research.

It also has a data partnership with Center for Data-Driven Discovery in Biomedicine to advance research in pediatric cancer and rare disease. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.

Stock analysis

Illumina Inc (ILMN) currently trades at $226.54, while our model-based Fair Value estimate is $262.03, implying the stock looks roughly 14% undervalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of $154.16 per share, and 1 of the 24 models we run sit above the $226.54 price.

Bear case: the Economic Profit group reads lowest at $49.13, and 23 of the 24 models stay below the price. Data coverage for this calculation is medium.

Scenario range: $145.54 (bear) to $355.23 (bull), the price of $226.54 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 83/100 (high quality), in the Healthcare sector.

Mixed Growth: Spin-off in 2024: revenue and profit before it include the divested business. Growth is measured afresh from 2024.

Illumina Inc reported revenue of $4.3B in FY2025 versus $4.5B in FY2021, a compound −1.1%/yr. Reported net income was $850M in FY2025, compounding +2.8%/yr from FY2021.

Key figures

Market cap $34.7B Large · P/E ratio 39.0 · P/S ratio 7.64 · EPS (TTM) $5.81 · Net margin 19.7% · Return on equity 32.4% · Return on assets (EBIT) −9.1% · Operating margin 20.0%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 77 out of 100 (low confidence).

What moves the price

The share trades about 23% below its 52-week high and 98% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −29% fair-value upside, at 16%, ILMN screens cheaper than that median.

Fair Value models

Bear $145.54 Fair Value $262.03 Bull $355.23
Price $226.54 · Upside +15.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($4.92 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF $89.38 $145.00 $291.52 76
Growth DCF $85.15 $156.37 $280.14 75
EPV $34.81 $39.96 $44.33 74
All 24 models by family
DCF Models
FCF DCF $89.38 $145.00 $291.52 76
Owner Earnings $79.36 $167.74 $336.03 71
5Y Revenue Exit $64.59 $114.63 $205.84 70
5Y EBITDA Exit $79.79 $147.83 $264.85 72
5Y P/E Exit $89.03 $179.64 $294.59 68
10Y Revenue Exit $70.17 $129.92 $202.93 65
10Y EBITDA Exit $82.11 $156.59 $287.64 65
10Y P/E Exit $88.23 $172.82 $314.41 61
Earnings-Based
Graham-Dodd $38.23 $260.88 $365.76 63
Lynch FV $76.66 $109.51 $142.36 61
PEG = 1.0 $76.66 $109.51 $142.36 57
EPV $34.81 $39.96 $44.33 74
Multiples
P/E Multiple $92.76 $123.68 $154.60 63
P/S Multiple $71.68 $95.57 $119.46 58
P/B Multiple $31.25 $41.67 $52.08 55
EV/EBIT $65.35 $89.64 $113.92 66
EV/EBITDA $71.24 $97.49 $123.74 67
EV/Revenue $44.49 $66.78 $89.06 53
Asset-Based
NCAV (Graham) $4.63 $6.20 $9.26 54
Growth DCF
Growth DCF $85.15 $156.37 $280.14 75
Rev-Margin DCF $64.59 $119.82 $201.19 70
Economic Profit
Residual Income $32.73 $49.13 $109.03 64
ROIC Compounder $42.07 $58.73 $80.98 71
Growth Earnings
Growth-Adj P/E $107.91 $154.16 $200.41 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 83/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 76
How much profit the company makes from its sales and capital
Quality Growth 61
Are margins and returns getting better?
Cashflow 78
Do the profits arrive as real cash?
Financial strength 70
Debt, balance sheet and risk of trouble
Investment 97
Does it invest with discipline instead of growing at any price?
Low Volatility 26
How calm the share price moves, does not count
Price momentum 90
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 81
Distance to the 52-week high, does not count
New shares 97
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 5 officers or directors sold shares worth $592.2M and none bought.

  • SaleKeith A. MeisterDirector6× since May 13, 2026: 3,059,258 shares, avg. $193.23$591.1MSep 4, 2026
  • SaleChristensen Jakob WedelSVP, Strategy/Corp Development3× since Dec 8, 2025: 2,282 shares, avg. $160.45$366,137Aug 18, 202610b5-1 plan
  • SaleScott M DaviesChief Legal Officer5× since Dec 12, 2025: 3,504 shares, avg. $151.62$531,274Jul 30, 202610b5-1 plan
  • SalePatricia LeckmanSVP, Chief People Officer3× since Feb 18, 2026: 3,937 shares, avg. $134.55$529,719Jun 5, 202610b5-1 plan
  • SaleScott D EricksenVP, Chief Accounting Officer2,000 shares at $152.58$305,150May 29, 202610b5-1 plan
  • BuyScott GottliebDirector200 shares at $117.81$23,562Feb 9, 2026

Plus 20 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 4, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 55/100
Spin-off in 2024: revenue and profit before it include the divested business. Growth is measured afresh from 2024.
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
+8.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year+8.7%
Dividend (yield on the price)0.0%
Per share before 2024divided by the spin-off factor 1.028
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.2.1% vs 6.1%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.12% → 20%
Pace: the 5-year rate starts in 2020 (pandemic)

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+23.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+6.1%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +20.1% a year for the price and +3.7% for the forecasts.
Forecast 2026 (sales)+6.8%
Forecast 2027 (sales)+6.9%
Projected 2028 (sales)+6.3%
Projected 2029 (sales)+5.7%
Projected 2030 (sales)+5.1%

Watch ILMN, get fair value alerts →

Recent news

News mood ⓘNews mood, the average tone of recent news (99 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Positive
Recent news coverage is more positive than average.
Note from the team Oct 31, 2026
AI conclusion: The business draws strength from robust clinical sequencing demand and fast NovaSeq X uptake, yet remains limited by ongoing mid-to-high-single-digit declines in research and applied markets.
Main risk: China's import ban on high-throughput sequencers and placement on the unreliable entities list could let rivals such as MGI and Berry Genomics capture procurement share, slowing renewal of the installed base and cutting consumables revenue.
Illumina is seeing strong clinical sequencing demand and rapid NovaSeq X adoption that pushed third-quarter results ahead of expectations and prompted raised 2026 guidance. Research and applied markets, however, continue their mid-to-high-single-digit declines. Will clinical momentum more than offset the persistent weakness elsewhere?
Join the discussion →

Compare Illumina Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 126 stocks

Beats the industry median on 6/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 83 · Top 25%
Fair Value upside +15.7% · Top 25%
Profitability
Return on equity (12 months) 32.4% · Top 25%
Return on assets 12.8% · Top 25%
Net margin (12 months) 19.7% · Top 25%
Operating margin (12 months) 20.0% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) 4.2% · Below median
Balance sheet
Debt / equity 0.55× · Highest 25%

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/E (12 months) 39.0× · Pricier than median
P/B 12.73× · Priciest 25%
P/S (12 months) 7.64× · Priciest 25%
Price / free cash flow 37.2× · Pricier than median
EV/EBITDA 30.4× · Priciest 25%
PEG 2.91× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)54 · sector 0
FUTURE (revenue growth)21 · sector 38
PAST (return on equity)100 · sector 15
HEALTH (low debt)73 · sector 95
DIVIDEND (yield)0 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
IQVIA Holdings IQV $263.79 $288.85 +10% vs ILMN
WuXi AppTec Co 603259 ¥154.46 ¥164.66 +7% vs ILMN
Thermo Fisher Scientific Inc TMO $706.16 $686.04 −3% vs ILMN
Danaher Corporation DHR $234.93 $209.18 −11% vs ILMN
IDEXX Laboratories, Inc IDXX $698.55 $496.48 −29% vs ILMN
Labcorp Holdings LH $367.79 $230.82 −37% vs ILMN
Mettler-Toledo International Inc MTD $1,723 $648.30 −62% vs ILMN
Agilent Technologies, Inc A $177.17 $64.53 −64% vs ILMN
Lonza Group LONN CHF 672.40 CHF 153.50 −77% vs ILMN
Waters Corporation WAT $467.60 $91.26 −80% vs ILMN

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Illumina Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Illumina Inc Fair Value". https://www.fairvalue-calculator.com/stock/ILMN

Frequently asked questions

Is Illumina Inc (ILMN) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of $262.03 versus a price of $226.54, about +16% upside (undervalued).
What is the fair value of ILMN?
Our model-based fair value for Illumina Inc is $262.03 (as of Nov 4, 2026), built from audited fundamentals. The current price: $226.54.
What is the quality score of ILMN?
Illumina Inc has a Quality Score of 83/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Illumina Inc (ILMN)?
Our model-based price target is the fair value of $262.03 (as of Nov 4, 2026) from 24 valuation models. Cautious scenario $145.54, optimistic scenario $355.23. It is a calculation from audited fundamentals, not an analyst target.
What is the Illumina Inc stock forecast for 2026?
Our models put fair value at $262.03, about +16% upside versus a price of $226.54 (undervalued). Cautious scenario $145.54, optimistic scenario $355.23. The calculation is refreshed regularly with new filings.
What is the revenue of Illumina Inc (ILMN)?
Illumina Inc reported trailing-twelve-month revenue of about $4.5B (latest available figure, as of Nov 4, 2026).
What growth is priced into Illumina Inc (ILMN)?
For today's price to be fair in a discounted-cash-flow model, Illumina Inc would have to grow free cash flow by +23.0 % per year for five years (discount rate 10.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +6.0 % per year. As of Nov 4, 2026.
What discount rate (WACC) does the fair value of ILMN use?
Our models discount Illumina Inc at 10.3 %: a base by market capitalisation (large), damped by beta 1.45, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Illumina Inc that is +23.0 % per year a year over ten years, using the same discount rate (10.3 %) and the same formula as our fair value.
How much growth has Illumina Inc (ILMN) delivered so far?
Over the past 5 years revenue at Illumina Inc grew +6.0 % a year. The price currently implies +23.0 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Illumina Inc (ILMN) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Illumina Inc (+23.0 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Illumina Inc (ILMN)?
The free-cash-flow yield on the price is 2.69 %: that much free cash flow Illumina Inc produces per unit of market value. When it exceeds the discount rate of our models (10.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Illumina Inc (ILMN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Illumina Inc it is $262.03 per share (as of Nov 4, 2026), against a price of $226.54. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Illumina Inc stock overvalued or undervalued in 2026?
As of Nov 4, 2026, ILMN trades below its calculated fair value: price $226.54, fair value $262.03, a gap of about +16% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ILMN?
No. The price is what the market pays today ($226.54); the fair value is what the company's own numbers justify ($262.03). For Illumina Inc the two are $35.49 per share apart. That gap is exactly why we show both numbers side by side.
How much is Illumina Inc worth?
The market values Illumina Inc at about $34.7B (market capitalisation, as of Nov 4, 2026). Per share that is $226.54; our models calculate a fair value of $262.03 per share.
What do the bullish and bearish scenarios say about ILMN?
Our models span a range for Illumina Inc: cautious scenario $145.54, base $262.03, optimistic $355.23 per share (as of Nov 4, 2026, price $226.54). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ILMN?
Illumina Inc trades at a price-to-earnings ratio of 39.0 (as of Nov 4, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $262.03 is built from several models across several years. Excluding one-off items of fiscal year 2025 it is 46.8 (reported for FY2025: 41.0). Other multiples: PEG 2.9, P/B 12.7, P/S 7.6, EV/EBITDA 30.4.
What is the PEG ratio of ILMN?
The PEG ratio of Illumina Inc is 2.91 (P/E divided by earnings growth, as of Nov 4, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Illumina Inc (ILMN)?
Balance-sheet figures for Illumina Inc (as of Nov 4, 2026): return on equity 32.4%, debt of 0.55 per unit of equity. They feed the Quality Score of 83/100, which measures business quality independently of the share price.
How far is ILMN from its 52-week high?
Illumina Inc trades at $226.54, about 23% below its 52-week high of $293.69 and 98% above the low of $114.44 (as of Nov 4, 2026). Distance from the high says nothing about value: that is what the fair value of $262.03 is for.
Which stocks are comparable to Illumina Inc?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Illumina Inc stock attractive at the current price?
The data as of Nov 4, 2026: price $226.54, calculated fair value $262.03 (+16%), Quality Score 83/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ILMN calculated?
We run Illumina Inc through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $262.03, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.6% above its aggregate fair value. Illumina Inc currently trades 14% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Illumina Inc (ILMN)?
The closing price on Nov 4, 2026 was $226.54. Our model-based fair value is $262.03, about +16% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Illumina Inc right now?
A fairly wide model range ($145.54 to $355.23) leaves room in how you read the outcome. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of Illumina Inc

How large is the market capitalisation of Illumina Inc (ILMN)?
The market capitalisation of Illumina Inc is $34.7B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Illumina Inc (ILMN)?
The price-to-sales ratio of Illumina Inc is 7.64 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Illumina Inc (ILMN)?
Earnings per share at Illumina Inc are $5.81 (price ÷ EPS = P/E 39.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Illumina Inc (ILMN)?
The net margin of Illumina Inc is 19.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Illumina Inc (ILMN)?
The return on equity (ROE) of Illumina Inc is 32.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Illumina Inc (ILMN)?
On an EBIT basis the return on assets of Illumina Inc is −9.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Illumina Inc (ILMN)?
The operating margin of Illumina Inc is 20.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Illumina Inc (ILMN)?
Revenue at Illumina Inc is growing +4.2% versus a year earlier (3y avg −1.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Illumina Inc (ILMN)?
Earnings per share at Illumina Inc are growing +45.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Illumina Inc (ILMN) carry?
The net debt of Illumina Inc is $1.1B (fiscal year 2025, ≈ 1.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Illumina Inc in the live analysis

One click puts Illumina Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.